文献速递认知障碍与痴呆

Tau PET在临床前及前驱期阿尔茨海默病中的预后准确性:与淀粉样蛋白PET及MRI的头对头比较

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
PubMed 文献 · JAMA Neurol · 2021-01-01

该预后研究纳入8个队列共1431名参与者,平均随访1.9年,比较基线tau PET(18F-flortaucipir或18F-RO948)、MRI和淀粉样蛋白PET对MMSE变化的预测能力。结果显示tau PET的预测效应量在全部参与者及Aβ阳性MCI和CU组中均优于MRI和淀粉样蛋白PET,且在18F-RO948队列中重复验证。

要点

  • Tau PET预测认知变化的效应量优于淀粉样蛋白PET和MRI。
  • 在Aβ阳性MCI和CU组中,tau PET的R2值均高于MRI和淀粉样蛋白PET。
  • MRI部分介导tau PET与认知变化的关联,尤其在AD痴呆和Aβ阳性MCI组。

核心结论

  • Tau PET是预测认知变化的有前景工具,优于淀粉样蛋白PET和MRI,可能支持AD临床前及前驱期的预后评估。

研究设计与样本

  • 预后研究,收集韩国、瑞典和美国8个队列2014年6月1日至2021年2月28日数据,平均随访1.9年。
  • 共纳入1431名参与者:673名认知未受损(CU,253名Aβ阳性),443名轻度认知障碍(MCI,271名Aβ阳性),315名AD痴呆(全部Aβ阳性)。
  • 暴露因素包括基线18F-flortaucipir PET(发现队列n=1135)或18F-RO948 PET(重复队列n=296)、T1加权MRI(n=1431)和淀粉样蛋白PET(n=1329)。

主要发现

  • 上述结果在18F-RO948 PET队列中重复验证。

临床怎么用

  • 在临床前和前驱期AD中,可考虑使用tau PET预测认知变化,其预后价值优于淀粉样蛋白PET和MRI。
  • 年龄较大者tau PET预后意义更强,解读结果时应考虑年龄因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tau positron emission tomography (PET) tracers have proven useful for the differential diagnosis of dementia, but their utility for predicting cognitive change is unclear. OBJECTIVE: To examine the prognostic accuracy of baseline fluorine 18 (18F)-flortaucipir and [18F]RO948 (tau) PET in individuals across the Alzheimer disease (AD) clinical spectrum and to perform a head-to-head comparison against established magnetic resonance imaging (MRI) and amyloid PET markers. DESIGN, SETTING, AND PARTICIPANTS: This prognostic study collected data from 8 cohorts in South Korea, Sweden, and the US from June 1, 2014, to February 28, 2021, with a mean (SD) follow-up of 1.9 (0.8) years. A total of 1431 participants were recruited from memory clinics, clinical trials, or cohort studies; 673 were cognitively unimpaired (CU group; 253 [37.6%] positive for amyloid-β [Aβ]), 443 had mild cognitive impairment (MCI group; 271 [61.2%] positive for Aβ), and 315 had a clinical diagnosis of AD dementia (315 [100%] positive for Aβ). EXPOSURES: [18F]Flortaucipir PET in the discovery cohort (n = 1135) or [18F]RO948 PET in the replication cohort (n = 296), T1-weighted MRI (n = 1431), and amyloid PET (n = 1329) at baseline and repeated Mini-Mental State Examination (MMSE) evaluation. MAIN OUTCOMES AND MEASURES: Baseline [18F]flortaucipir/[18F]RO948 PET retention within a temporal region of interest, MRI-based AD-signature cortical thickness, and amyloid PET Centiloids were used to predict changes in MMSE using linear mixed-effects models adjusted for age, sex, education, and cohort. Mediation/interaction analyses tested whether associations between baseline tau PET and cognitive change were mediated by baseline MRI measures and whether age, sex, and APOE genotype modified these associations. RESULTS: Among 1431 participants, the mean (SD) age was 71.2 (8.8) years; 751 (52.5%) were male. Findings for [18F]flortaucipir PET predicted longitudinal changes in MMSE, and effect sizes were stronger than for AD-signature cortical thickness and amyloid PET across all participants (R2, 0.35 [tau PET] vs 0.24 [MRI] vs 0.17 [amyloid PET]; P < .001, bootstrapped for difference) in the Aβ-positive MCI group (R2, 0.25 [tau PET] vs 0.15 [MRI] vs 0.07 [amyloid PET]; P < .001, bootstrapped for difference) and in the Aβ-positive CU group (R2, 0.16 [tau PET] vs 0.08 [MRI] vs 0.08 [amyloid PET]; P < .001, bootstrapped for difference). These findings were replicated in the [18F]RO948 PET cohort. MRI mediated the association between [18F]flortaucipir PET and MMSE in the groups with AD dementia (33.4% [95% CI, 15.5%-60.0%] of the total effect) and Aβ-positive MCI (13.6% [95% CI, 0.0%-28.0%] of the total effect), but not the Aβ-positive CU group (3.7% [95% CI, -17.5% to 39.0%]; P = .71). Age (t = -2.28; P = .02), but not sex (t = 0.92; P = .36) or APOE genotype (t = 1.06; P = .29) modified the association between baseline [18F]flortaucipir PET and cognitive change, such that older individuals showed faster cognitive decline at similar tau PET levels. CONCLUSIONS AND RELEVANCE: The findings of this prognostic study suggest that tau PET is a promising tool for predicting cognitive change that is superior to amyloid PET and MRI and may support the prognostic process in preclinical and prodromal stages of AD.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Ossenkoppele R, Smith R, Mattsson-Carlgren N, et al. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. JAMA Neurol. 2021. PMID: 34180956. doi:10.1001/jamaneurol.2021.1858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。